{"id":18438,"date":"2014-04-01T13:10:52","date_gmt":"2014-04-01T17:10:52","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=18438"},"modified":"2014-04-01T13:24:07","modified_gmt":"2014-04-01T17:24:07","slug":"tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438","title":{"rendered":"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 04\/01\/2014 (wallstreetpr) \u00a0\u2013 morning trading session, moving up by highs of $18.65%. The huge gains comes at the back of Tetralogic announcing that data published in the April issue of <i>Molecular Cancer Therapeutics<\/i>, further advances the company\u2019s lead SMAC-Mimetic Birianapant.<\/p>\n<p style=\"text-align: justify;\">The product is currently under Phase 1 and Phase II clinical trials in a bid of trying to find its <b>Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)\u2019s <\/b>stock has been one of the top gainers in effectiveness in the treatment of hematological malignancies as well as Solid Tumors.<\/p>\n<p style=\"text-align: justify;\">The company has already been impressed with the results of the studies which continue to support a combination of Birianapant for multiple chemotherapies. Data from the studies indicate that Birianapant has the potential to be used in a wide variety of Cancers.<\/p>\n<p style=\"text-align: justify;\"><b>Tetralogic Pharmaceuticals CEO Wins an Award <\/b><\/p>\n<p style=\"text-align: justify;\">Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) in other news has also confirmed that it\u2019s President and Chief Executive Officer J. Kevin Buchi will attend the 13<sup>th<\/sup> Annual Needham Healthcare Conference to be held on April 8, 2014 and is expected to make a presentation.<\/p>\n<p style=\"text-align: justify;\">Tetralogic\u2019s CEO Kevin Buchi was recently recognized for his achievements and contribution towards the pharmaceutical industry consequently winning the CEO of the year award, awarded byPennsylvania Bio. The award recognizes CEO\u2019s who have shown splendid and visionary leadership achievement throughout the year while showing commitments to patients and the industry.<\/p>\n<p style=\"text-align: justify;\"><b>Sungy Mobile Ltd (NASDAQ:GOMO) Continues to Surge in the market<\/b><\/p>\n<p style=\"text-align: justify;\"><b>Sungy Mobile Ltd (NASDAQ:GOMO)<\/b> best known for its Product GO launcher EX, continues to surge in the market at the back of huge traded volumes as the company continues to reap on its recently released financial results. The company\u2019s shares have already gained by highs of 18.22% in Intraday trading session and looks set to continue rallying.<\/p>\n<p style=\"text-align: justify;\">The company\u2019s mobile product and services continue to perform well online and for the first time in the company\u2019s history, accounted 50% of the company\u2019s total revenue. The accomplishment in this case highlighted Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)\u2019s improved user experience. The quality of user experience has already driven the company\u2019s ability to expand its broadband app\u2019s adaption. Looking ahead, Sungy Mobile plans to expand its user base through the strengthening of its Go platform.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 04\/01\/2014 (wallstreetpr) \u00a0\u2013 morning trading session, moving up by highs of $18.65%. The huge gains comes at the back of Tetralogic announcing that [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":18439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[4563,5768,4562,5767],"stock_ticker":[],"class_list":["post-18438","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqgomo","tag-nasdaqtlog","tag-sungy-mobile-ltd-nasdaqgomo","tag-tetralogic-pharmaceuticals-corp-nasdaqtlog","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 04\/01\/2014 (wallstreetpr) \u00a0\u2013 morning trading session, moving up by highs of $18.65%. The huge gains comes at the back of Tetralogic announcing that [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-01T17:10:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-04-01T17:24:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"530\" \/>\n\t<meta property=\"og:image:height\" content=\"298\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant\",\"datePublished\":\"2014-04-01T17:10:52+00:00\",\"dateModified\":\"2014-04-01T17:24:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg\",\"keywords\":[\"NASDAQ:GOMO\",\"NASDAQ:TLOG\",\"Sungy Mobile Ltd (NASDAQ:GOMO)\",\"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438\",\"name\":\"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg\",\"datePublished\":\"2014-04-01T17:10:52+00:00\",\"dateModified\":\"2014-04-01T17:24:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg\",\"width\":530,\"height\":298},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438","og_locale":"en_US","og_type":"article","og_title":"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant - Wall Street PR","og_description":"Boston, MA 04\/01\/2014 (wallstreetpr) \u00a0\u2013 morning trading session, moving up by highs of $18.65%. The huge gains comes at the back of Tetralogic announcing that [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-04-01T17:10:52+00:00","article_modified_time":"2014-04-01T17:24:07+00:00","og_image":[{"width":530,"height":298,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant","datePublished":"2014-04-01T17:10:52+00:00","dateModified":"2014-04-01T17:24:07+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg","keywords":["NASDAQ:GOMO","NASDAQ:TLOG","Sungy Mobile Ltd (NASDAQ:GOMO)","Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438","url":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438","name":"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg","datePublished":"2014-04-01T17:10:52+00:00","dateModified":"2014-04-01T17:24:07+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/101267587-63e9f3a46b9037015afb3744088ca025f996428f.530x298.jpg","width":530,"height":298},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tetralogic-pharmaceuticals-corp-nasdaqtlog-announces-publication-of-preclinical-characterization-of-birianapant-18438#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Announces Publication of Preclinical Characterization of Birianapant"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/18438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=18438"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/18438\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/18439"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=18438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=18438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=18438"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=18438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}